Long-form phosphodiesterase 4 isoforms (PDE4 long isoforms) (PDE4 long isoforms)

Long-form phosphodiesterase 4 (PDE4) isoforms are a specific class of cAMP-degrading enzymes characterized by the presence of two N-terminal regulatory domains, Upstream Conserved Regions 1 and 2 (UCR1 and UCR2) [2, 11]. These long isoforms are unique because they can form functional dimers and are specifically activated through phosphorylation by Protein Kinase A (PKA) on the UCR1 domain, providing a critical negative feedback loop to terminate cAMP signaling [11, 15]. PDE4 is the predominant cAMP-degrading enzyme in immune cells, where it regulates the production of pro-inflammatory cytokines like TNF-alpha and interleukins [1, 18]. Consequently, PDE4 long isoforms are major therapeutic targets for chronic inflammatory diseases such as chronic obstructive pulmonary disease (COPD), psoriasis, and atopic dermatitis [4, 10]. Drugs like roflumilast and apremilast work by inhibiting these enzymes to elevate intracellular cAMP levels and dampen inflammatory responses [14, 17]. However, broad inhibition of PDE4 isoforms, particularly in the central nervous system, is associated with significant safety concerns, most notably dose-limiting nausea and emesis [9, 16].

Other names

PDE4 long variantsUCR1-UCR2 containing PDE4Dimeric PDE4 isoformsPhosphodiesterase 4 long forms

Inhibition of cyclic adenosine monophosphate (cAMP) hydrolysis, leading to increased intracellular cAMP levels and subsequent suppression of pro-inflammatory cytokine production.